AU2013257707A1 - Compositions and methods for the treatment of epilepsy - Google Patents

Compositions and methods for the treatment of epilepsy Download PDF

Info

Publication number
AU2013257707A1
AU2013257707A1 AU2013257707A AU2013257707A AU2013257707A1 AU 2013257707 A1 AU2013257707 A1 AU 2013257707A1 AU 2013257707 A AU2013257707 A AU 2013257707A AU 2013257707 A AU2013257707 A AU 2013257707A AU 2013257707 A1 AU2013257707 A1 AU 2013257707A1
Authority
AU
Australia
Prior art keywords
disorder
administration
formula
compositions
seizures
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2013257707A
Other languages
English (en)
Inventor
Mahesh Kandula
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cellix Bio Pvt Ltd
Original Assignee
Cellix Bio Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellix Bio Pvt Ltd filed Critical Cellix Bio Pvt Ltd
Publication of AU2013257707A1 publication Critical patent/AU2013257707A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24Oxygen or sulfur atoms
    • C07D207/262-Pyrrolidones
    • C07D207/2632-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/272-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2013257707A 2012-05-08 2013-01-29 Compositions and methods for the treatment of epilepsy Abandoned AU2013257707A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN1791/CHE/2012 2012-05-08
IN1791CH2012 2012-05-08
PCT/IB2013/050740 WO2013167986A2 (fr) 2012-05-08 2013-01-29 Compositions et méthodes de traitement de l'épilepsie

Publications (1)

Publication Number Publication Date
AU2013257707A1 true AU2013257707A1 (en) 2014-11-27

Family

ID=54187089

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013257707A Abandoned AU2013257707A1 (en) 2012-05-08 2013-01-29 Compositions and methods for the treatment of epilepsy

Country Status (7)

Country Link
EP (1) EP2846795A2 (fr)
JP (1) JP2015526385A (fr)
AU (1) AU2013257707A1 (fr)
CA (1) CA2873016A1 (fr)
SG (1) SG11201407309XA (fr)
WO (1) WO2013167986A2 (fr)
ZA (1) ZA201408058B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2873094A1 (fr) * 2012-05-07 2013-11-14 Cellixbio Private Limited Promedicaments d'agents antiplaquettaires
SG11201407328TA (en) * 2012-07-03 2014-12-30 Cellix Bio Private Ltd Compositions and methods for the treatment of moderate to severe pain
CA2950788C (fr) 2014-06-02 2022-10-04 Ketogen Inc. Composes pour le traitement de crises epileptiques et d'autres troubles et affections du systeme nerveux central

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9708394A (es) * 1995-05-05 1998-02-28 Novo Nordisk As Composicion farmaceutica que contiene clorhidrato de tiagabina y el proceso para su preparacion.
WO2006062980A2 (fr) * 2004-12-07 2006-06-15 Nektar Therapeutics Formulation non cristalline stable comprenant de la tiagabine
US8338621B2 (en) * 2005-12-21 2012-12-25 Ucb S.A. Process for the preparation of 2-oxo-1-pyrrolidine derivatives
WO2010132693A2 (fr) * 2009-05-13 2010-11-18 Nektar Therapeutics Composés pyrrolidine contenant un oligomère

Also Published As

Publication number Publication date
EP2846795A2 (fr) 2015-03-18
CA2873016A1 (fr) 2013-11-14
WO2013167986A2 (fr) 2013-11-14
SG11201407309XA (en) 2014-12-30
ZA201408058B (en) 2016-03-30
WO2013167986A3 (fr) 2015-06-18
JP2015526385A (ja) 2015-09-10

Similar Documents

Publication Publication Date Title
US9499527B2 (en) Compositions and methods for the treatment of familial amyloid polyneuropathy
AU2013257717A1 (en) Compositions and methods for the treatment of metabolic syndrome
WO2014087367A2 (fr) Compositions et procédés pour le traitement de maladies neurologiques et de leurs complications associées
WO2014068463A2 (fr) Compositions et procédés de traitement d'une inflammation et de troubles métaboliques
US9738631B2 (en) Compositions and methods for the treatment of neurological disorders
AU2013257707A1 (en) Compositions and methods for the treatment of epilepsy
WO2015033279A1 (fr) Compositions et méthodes pour le traitement de l'homocystinurie
US20150141500A1 (en) Compositions and methods for the treatment of neurological diseases
WO2014097137A2 (fr) Compositions et méthodes destinées à traiter les avc et autres maladies neurologiques
WO2014195850A2 (fr) Compositions et méthodes de traitement de maladies neurologiques et de troubles neurologiques
WO2014068506A2 (fr) Compositions et procédés pour le traitement de maladies autoimmunes
AU2013257710A1 (en) Compositions and methods for the treatment of neurological disorders
US9242939B2 (en) Compositions and methods for the treatment of respiratory disorders
CA2873094A1 (fr) Promedicaments d'agents antiplaquettaires
WO2014068459A2 (fr) Compositions et méthodes de traitement de la douleur et de maladies neurologiques
WO2014057439A2 (fr) Compositions et procédés de traitement de maladies neurologiques et des complications associées
WO2014068461A2 (fr) Compositions et méthodes de traitement d'une inflammation aiguë
US9290486B1 (en) Compositions and methods for the treatment of epilepsy
US9187427B2 (en) N-substituted nicotinamide compounds and compositions for the treatment migraine and neurologic diseases
WO2013179153A1 (fr) Compositions et méthodes de traitement de troubles neurologiques dégénératifs et de maladies neurologiques
US9303038B2 (en) Compositions and methods for the treatment of epilepsy and neurological diseases
AU2013311349A1 (en) Compositions and methods for treatment of inflammation and lipid disorders
US9266823B2 (en) Compositions and methods for the treatment of parkinson's disease
WO2014122575A2 (fr) Conjugués d'acide gras pour le traitement d'inflammations et de maladies métaboliques
WO2013167999A2 (fr) Compositions et méthodes de traitement d'affections neurologiques

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period